'Microdosing' GLP-1s can shed pounds, but here are the dangers

Key Points:

• New research indicates that microdosing popular GLP-1 weight-loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide) can lead to some weight loss, though significantly less than the reductions seen at FDA-approved maintenance doses.
• The study, involving over 500 patients on low starter doses over six months, found average weight loss of 5.5% with tirzepatide and 2.2% with semaglutide, compared to much higher losses in clinical trials using recommended doses.
• Side effects occurred even at low doses, with tirzepatide users experiencing higher rates of kidney injury and other issues, while semaglutide users had more ear inflammation and swelling; both drugs require careful dose escalation per manufacturer guidelines.
• Experts emphasize the need for patients to consult healthcare providers before microdosing, as evidence on benefits and risks remains limited and inconsistent, leaving doctors uncertain about recommending low-dose regimens.
• Ongoing studies, including a Novo Nordisk trial on lower maintenance doses of Wegovy, aim to clarify safety and efficacy, but results may take years, leaving patients and physicians currently navigating microdosing with limited clinical guidance.